Enveric Biosciences Expands Patent Protection for EVM301 Portfolio
Enveric Biosciences (NASDAQ: ENVB) is making remarkable strides in the biotechnology sector with its commitment to developing novel neuroplastogens aimed at treating neuropsychiatric disorders. This dedication has led to the expansion of its patent portfolio with the issuance of five new U.S. patents, as well as the allowance of three additional patent applications from the United States Patent and Trademark Office.
Significant Growth in Patent Issuance
The newly issued U.S. Patent Nos. 11,845,727; 11,858,895; 11,891,359; 11,998,557, and 12,128,058, join four previously announced patents, bringing the total to an impressive nine U.S. patents covering the EVM301 portfolio and its diverse drug candidate library. A standout feature of this portfolio is Enveric's Psybrary™, a unique catalogue encompassing over 1,000 tryptamine derivative molecules. This catalogue effectively combines receptor engagement with functional data, helping to establish correlations between structure and biological activity.
CEO Comments on Portfolio Expansion
Dr. Joseph Tucker, CEO of Enveric, expressed enthusiasm regarding the extensive depth of the EVM301 portfolio, stating, "The increasing depth and breadth of the EVM301 portfolio of molecules with strong intellectual property backing expands the value-capture opportunities available to Enveric." He elaborated on the portfolio’s composition, which includes various tryptamine derivative molecules that are carboxylated, aminated, prenylated, and halogenated, among others. This range also considers combinations of these functional motifs in multi-substituent forms.
Advancements in Drug Discovery
Enveric’s innovative drug discovery engine has revealed compounds with an enhanced focus on 5-HT2C receptors. Several molecules in their portfolio, protected by issued patent claims, are being explored as candidates for treating epilepsy and obesity, given their notable binding preference for the 5-HT2C receptor compared to other targets.
Preclinical Development of EB-003
Among the most promising candidates from the EVM301 portfolio is EB-003, which addresses significant mental health conditions, including treatment-resistant depression and anxiety. Currently in preclinical development, EB-003 aims to support the filing of an Investigational New Drug (IND) application by 2025. Receptor engagement data has demonstrated a favorable safety profile for EB-003, indicating that it may promote neuroplasticity without causing hallucinations—an important consideration for ensuring patient safety in therapeutic contexts.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is committed to the development of over-the-counter small-molecule therapeutics specifically targeted towards treating disorders such as depression, anxiety, and addiction. Utilizing its cutting-edge discovery platform, Psybrary™, the company has successfully built a robust intellectual property portfolio centered around new chemical entities tailored for critical mental health challenges. Additionally, Enveric is developing EB-002, a synthetic prodrug of psilocin, aimed at offering new avenues for psychiatric disorder treatments. Headquartered in Naples, FL, with offices in Cambridge, MA, and Calgary, AB, Canada, Enveric continues to advance its innovative research to improve patient outcomes. For more information about Enveric Biosciences, please visit www.enveric.com.
Frequently Asked Questions
What is Enveric Biosciences focused on?
Enveric Biosciences focuses on developing novel neuroplastogenic therapeutics for treating mental health disorders including depression, anxiety, and addiction.
How many patents does Enveric Biosciences hold for its EVM301 portfolio?
Enveric Biosciences currently holds a total of nine U.S. patents covering its EVM301 portfolio and associated drug candidates.
What is the main candidate in the EVM301 portfolio?
EB-003 is the lead candidate from the EVM301 portfolio, targeting treatment-resistant depression and anxiety, currently in preclinical development.
What safety concerns are associated with EB-003?
EB-003 has shown a favorable safety profile and is designed to promote neuroplasticity while avoiding the risk of inducing hallucinations.
Where is Enveric Biosciences headquartered?
Enveric Biosciences is headquartered in Naples, Florida, with additional offices in Cambridge, Massachusetts, and Calgary, Alberta, Canada.
